{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:25:35Z","timestamp":1794104735480,"version":"4.8.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"\n Importance<\/jats:title>\n Cardiovascular inflammation is a major determinant of atherosclerotic disease, and inhibition of the central signaling cytokine, interleukin 6 (IL-6), is a promising target for intervention. Patients with chronic kidney disease (CKD) commonly have plasma elevations of inflammatory biomarkers, such as high-sensitivity C-reactive protein (hsCRP) and IL-6, and are at high risk for life-threatening atherosclerotic events as well as loss of kidney function and might therefore benefit from IL-6 inhibition.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n The Ziltivekimab Cardiovascular Outcomes Trial (ZEUS;\n NCT05021835<\/jats:ext-link>\n ) will determine the safety and efficacy of IL-6 inhibition with ziltivekimab among patients with atherosclerotic cardiovascular disease (ASCVD), CKD, and systemic inflammation. ZEUS is a multinational, double-blind, placebo-controlled, event-driven, randomized clinical trial inclusive of 6376 participants with ASCVD, CKD, and an hsCRP level greater than or equal to 2 mg\/L who were randomized in a 1:1 fashion to receive either ziltivekimab, 15 mg, administered subcutaneously every month or matching placebo. At randomization, mean age was 69.5 years, 27.5% were female, 92.0% had hypertension, 65.7% had diabetes, and 41.3% had heart failure. At baseline, the mean estimated glomerular filtration rate (eGFR) was 44.5 mL\/min\/1.73 m\n 2<\/jats:sup>\n , mean low-density lipoprotein cholesterol level was 77.7 mg\/dL, median hsCRP level was 4.5 mg\/L, and median IL-6 level was 4.9 pg\/mL. At enrollment, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were being used by 36.8% and 11.3% of the cohort, respectively. The primary outcome is 3-point major adverse cardiovascular events. Secondary cardiovascular outcomes include (1) an expanded major adverse cardiovascular event outcome including hospitalization for unstable angina requiring urgent coronary revascularization, (2) hospitalizations for heart failure or urgent heart failure visits or cardiovascular death, and (3) all-cause mortality. The secondary kidney outcome is a composite of greater than 40% decline in eGFR, eGFR less than 15 mL\/min\/1.73 m\n 2<\/jats:sup>\n , dialysis, kidney transplant, death from kidney disease, or cardiovascular death.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The ZEUS randomized clinical trial will formally test the hypothesis that IL-6 inhibition with ziltivekimab will lower incident cardiovascular event rates and potentially slow kidney decline among participants with known ASCVD, CKD, and elevated hsCRP. If successful, the ZEUS trial would provide a fully novel approach for prevention of myocardial infarction, stroke, cardiovascular death, and kidney function decline among high-risk patients with CKD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.4491","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:26Z","timestamp":1765382426000},"page":"89","source":"Crossref","is-referenced-by-count":87,"title":["Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial"],"prefix":"10.1001","volume":"11","author":[{"given":"Paul M","family":"Ridker","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M. M.","family":"Baeres","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hvelplund","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads M. D.","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Department of Medicine, UT Southwestern Medical Center, Dallas, Texas"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"University of New South Wales Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"hsc250003r1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women.","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"issue":"10384","key":"hsc250003r2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of 3 randomized trials.","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"hsc250003r3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance.","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"hsc250003r4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study.","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"hsc250003r5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis.","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ Res"},{"issue":"48","key":"hsc250003r6","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1093\/eurheartj\/ehz283","article-title":"Immunotherapy for cardiovascular disease.","volume":"40","author":"Lutgens","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"hsc250003r7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease.","volume":"25","author":"Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"hsc250003r8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"hsc250003r9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"hsc250003r10","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1\u00df by canakinumab and cardiovascular outcomes in patients with chronic kidney disease.","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"hsc250003r11","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signaling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"hsc250003r12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis.","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"hsc250003r13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"hsc250003r14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomization analysis.","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"hsc250003r15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamacardio.2018.2287","article-title":"Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: a phenome-wide association study.","volume":"3","author":"Cai","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"11","key":"hsc250003r16","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease.","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"issue":"7","key":"hsc250003r17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week.","volume":"82","author":"Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hsc250003r18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomized trials.","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"42","key":"hsc250003r19","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"46","key":"hsc250003r20","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"hsc250003r21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation.","volume":"77","author":"Tuttle","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"hsc250003r22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study.","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"15","key":"hsc250003r23","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"hsc250003r24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"hsc250003r25","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/ndt\/17.9.1684","article-title":"Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment.","volume":"17","author":"Pecoits-Filho","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"hsc250003r26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/ki.2009.503","article-title":"Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.","volume":"77","author":"Barreto","year":"2010","journal-title":"Kidney Int"},{"key":"hsc250003r27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update.","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"hsc250003r28","doi-asserted-by":"publisher","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.","volume":"312","author":"Pichler","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"hsc250003r29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/cvr\/cvq078","article-title":"Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice.","volume":"87","author":"Kobara","year":"2010","journal-title":"Cardiovasc Res"},{"key":"hsc250003r30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fcvm.2017.00084","article-title":"An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice.","volume":"4","author":"Akita","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"hsc250003r31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167195","article-title":"Inhibition of interleukin-6 receptor in a murine model of myocardial ischemia-reperfusion.","volume":"11","author":"Hartman","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"hsc250003r32","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1161\/ATVBAHA.125.322533","article-title":"Direct interlukin-6 inhibition blunts arterial thrombosis by reducing collagen-mediated platelet activation.","volume":"45","author":"Ministrini","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"30","key":"hsc250003r33","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non\u2013ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"issue":"15","key":"hsc250003r34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with Acute ST-Segment Elevation Myocardial Infarction (ASSAIL-MI).","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hsc250003r35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jacc.2021.11.020","article-title":"Genetic IL-6 signaling modifies incident coronary artery disease risk in chronic kidney disease.","volume":"79","author":"Yu","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hsc250003r36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s44161-025-00700-7","article-title":"IL-6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk.","volume":"4","author":"Zhang","year":"2025","journal-title":"Nat Cardiovasc Res"},{"issue":"4","key":"hsc250003r37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.125.005103","article-title":"Human genetics informing drug development in cardiovascular disease: interleukin-6 signaling as a case study.","volume":"18","author":"de Goma","year":"2025","journal-title":"Circ Genom Precis Med"},{"issue":"6","key":"hsc250003r38","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/bcp.15191","article-title":"Dissecting the IL-6 pathway in cardiometabolic disease: a mendelian randomization study on both IL-6 and IL-6R.","volume":"88","author":"Cupido","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"hsc250003r39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine.","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"10289","key":"hsc250003r40","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"hsc250003r41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","article-title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial.","volume":"82","author":"Wada","year":"2023","journal-title":"J Cardiol"},{"issue":"2","key":"hsc250003r42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","article-title":"Association of interleukin-6 inhibition with ziltivekimab and the neutrophil-lymphocyte ratio: a secondary analysis of the RESCUE clinical trial.","volume":"8","author":"Adamstein","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hsc250003r43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from 5 contemporary randomized trials.","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"hsc250003r44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1681\/ASN.2020050595","article-title":"Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial.","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"hsc250003r45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE).","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"4S","key":"hsc250003r46","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"hsc250003r47","unstructured":"A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS). ClinicalTrials.gov identifier: NCT05021835. Updated September 25, 2025. Accessed November 5, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05021835"},{"key":"hsc250003r48","unstructured":"A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES). ClinicalTrials.gov identifier: NCT05636176. Updated October 20, 2025. Accessed November 5, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05636176"},{"key":"hsc250003r49","unstructured":"ARTEMIS\u2014A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack (ARTEMIS). ClinicalTrials.gov identifier: NCT06118281. Updated October 20, 2025. Accessed November 5, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06118281"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2842746\/jamacardiology_ridker_2025_sc_250003_1776953463.57247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:00:26Z","timestamp":1777474826000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2842746"}},"subtitle":["Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction"],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.4491","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}